NCT03416816View on ClinicalTrials.gov

A Study of DSP-0337 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile

PHASE1TerminatedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

May 15, 2018

Primary Completion Date

June 15, 2020

Study Completion Date

June 15, 2020

Conditions
Neoplasms
Interventions
DRUG

DSP-0337

DSP-0337 will be administered at the following doses in dose-escalation cohorts, maximum tolerated dose (MTD) for food effect, and recommended phase 2 dose (RP2D) for dose-expansion cohort. Dose 1: 200 mg once daily, Dose 2: 200 mg twice daily, Dose 3: 400 mg twice daily, Dose 4: 600 mg twice daily, Dose 5: 800 mg twice daily, Dose 6: 1000 mg twice daily.

Trial Locations (4)

46202

Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis

48201

Karmos Cancer Center, Detroit

78229

UT Heatlh San Antonio, San Antonio

84088

Utah Cancer Specialist, West Jordan

Sponsors

Collaborators (1)

Syneos Health
All Listed Sponsors
collaborator

Syneos Health

OTHER

lead

Sumitomo Pharma America, Inc.

INDUSTRY

NCT03416816 - A Study of DSP-0337 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile | Biotech Hunter | Biotech Hunter